A biosimilar mucus model to evaluate the diffusion of drugs for more efficient cystic fibrosis therapies

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1707522 since 2019-07-27T19:14:02Z

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
A BIOSIMILAR MUCUS MODEL TO EVALUATE THE DIFFUSION OF DRUGS FOR MORE EFFICIENT CYSTIC FIBROSIS THERAPIES

Cosmin Butnarasu, A Maura Vallaro, A Daniela Pacheco, B Paola Petriti, B Livia Visai A and Sonja Visentin A

A) Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino, 10125, Italy
B) Dipartimento di Chimica, Materiai e Ingegneria Chimica, Politecnico di Milano, 20133, Italy
C) Dipartimento di Medicina Molecolare, Università degli Studi di Pavia, 27100, Italy
E-mail: cosminstefan.butnarasu@unito.it

INTRODUCTION

The orally taken systemic drugs must pass through the gastrointestinal mucus barrier, whereas inhaled drugs must pass through airway mucus and their pulmonary deposition to reach their targets. Due to the wide variety of functional groups present in the mucin structure (Figure 2a), many interactions can be established with molecules of hydrophilic as well as hydrophobic nature [4] and association (Kd) and dissociation (Kd) can be obtained (Figure 2b). Therefore, the design of effective cystic fibrosis drugs must take into account the interaction of the potential candidates with mucin, and the diffusion across the mucus layer. The need to characterize drug behavior in a rapid, simple and reproducible manner has urged the development of airway mucus models. In this work, we investigate the affinity of some drugs to mucin and an airway mucus model composed by alginate and mucin, which aim to model both composition and rheological properties of the pathologic CF-mucus, is developed.

A. INTRODUCTION

The orally taken systemic drugs must pass through the gastrointestinal mucus barrier, whereas inhaled drugs must pass through airway mucus and their pulmonary deposition to reach their targets. Due to the wide variety of functional groups present in the mucin structure (Figure 2a), many interactions can be established with molecules of hydrophilic as well as hydrophobic nature [4] and association (Kd) and dissociation (Kd) can be obtained (Figure 2b). Therefore, the design of effective cystic fibrosis drugs must take into account the interaction of the potential candidates with mucin, and the diffusion across the mucus layer. The need to characterize drug behavior in a rapid, simple and reproducible manner has urged the development of airway mucus models. In this work, we investigate the affinity of some drugs to mucin and an airway mucus model composed by alginate and mucin, which aim to model both composition and rheological properties of the pathologic CF-mucus, is developed.

B. MUCIN-ANTIMICROBIC DRUGS INTERACTION

Since mucin is the mainly expressed glycoprotein within mucus, the protein-drug interaction may have an important role on the drug pharmacokinetics as a strong bond with mucin may results in a reduced drug absorption, hence a low drug efficacy. The determination of the extent of the interaction between the dataset drugs with a mucin solution was measured using two spectrophotometric methods: UV-VIS absorption and fluorescence spectra of mucin upon increasing concentration of drugs were registered. Kd and Kd constants were calculated by using the Stern-Volmer equation (Figure 3).

C. RESULTS

Ceftazidime, aztreonam, CFTRinh(1-72) and levofloxacin showed to interact with mucin whereas no interaction was detected in presence of rifampicin, tobramycin and ampiillin. The values of association constant are all in the same order of magnitude. Contrary to what was expected, the charge of the molecule seems to play not such a fundamental role upon interaction with mucin, in fact positively charged molecules at pH 7.4, such as tobramycin, have no interaction, whereas negatively charged drugs such as CFTRinh(1-72) or aztreonam can interact. This suggest that the binding to mucin could not be due only to electrostatic interactions but other factors as lipophilicity or H-bonding may play an important role. All the tested drugs have high hydrophilicity, in fact the value of logD7.4 are all negative (except for CFTRinh(1-72) and rifampicin). CFTRinh(1-72) which has exhibited the higher affinity is also the most hydrophilic at pH 7.4. The biosimilar mucus was employed also in PAMPA test, and the permeability of some drugs was measured in absence and in presence of mucin. Compared to a highly permeable compound (propanolol) the drugs we tested are low permeable already in absence of mucus and consequently the permeability is less influenced by mucus if compared to propanolol(Figure 6).

D. CONCLUSIONS

Even though some of the antibiotics herein investigated (ceftazidime, aztreonam, levofloxacin) can interact with mucin, the order of magnitude of Kd is quite low (Table 1) while tobramycin showed no affinity to mucin. All these data could in part explain why these antimicrobial drugs are the most employed antibiotics in CF. The low affinity of the tested drugs could be in part explained by their high hydrophilicity. However, in order to obtain a structure-affinity relationship a broader database should be investigated.